Is Anemic Growth Sending Novo Nordisk After Global Blood Therapeutics?

 
• By Sten Stovall

Once high-flying Novo Nordisk has been sending out M&A signals as it seeks a solution to weak growth, so analysts aren't surprised to see the Danish diabetes giant stalking US-based Global Blood Therapeutics.

Blood type medical concept with doctor in the background and blood drop from his finger

More from Deals

More from Business